Masashi Aonuma

1.8k citations

14 papers · 1.5k indexed · 1 hit paper · h-index 11

Co-authors: Yasuyoshi Kawato Keiki Sato Yasuhide Hirota Hiroshi Kuga Tomoko Takahashi Masabumi Shibuya Sachiko Yamaguchi Kensuke Matsumoto
Topics: Cancer-related Molecular Pathways (5 papers)Cancer therapeutics and mechanisms (4 papers)Click Chemistry and Applications (4 papers)
Cited by: Toxicology Oncology Molecular Biology
Journals: Oncogene Bioorganic & Medicinal Chemistry Bioorganic & Medicinal Chemistry Letters
Partner nations: Japan Germany United States

In The Last Decade

Masashi Aonuma

14 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.

1991 762 citations Yasuyoshi Kawato, Masashi Aonuma et al. PubMed profile →

Peers

Countries citing papers authored by Masashi Aonuma

Since Specialization

Citations

This map shows the geographic impact of Masashi Aonuma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masashi Aonuma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masashi Aonuma more than expected).

Fields of papers citing papers by Masashi Aonuma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masashi Aonuma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masashi Aonuma. The network helps show where Masashi Aonuma may publish in the future.

Co-authorship network of co-authors of Masashi Aonuma

This figure shows the co-authorship network connecting the top 25 collaborators of Masashi Aonuma. A scholar is included among the top collaborators of Masashi Aonuma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masashi Aonuma. Masashi Aonuma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Discovery of DS-5272 as a promising candidate: A potent and orally active p53–MDM2 interaction inhibitor 2015 ·Bioorganic & Medicinal Chemistry ·Masaki Miyazaki,Kouichi Uoto,(unknown),Hiroyuki Naito,Keisuke Yoshida,(unknown),Haruko C. Kawato,(unknown),(unknown),Mayumi Kitagawa,Takahiko Seki,(unknown),Masashi Aonuma,Tsunehiko Soga	31
2	Synthesis and evaluation of novel orally active p53–MDM2 interaction inhibitors 2013 ·Bioorganic & Medicinal Chemistry ·Masaki Miyazaki,Hiroyuki Naito,(unknown),Keisuke Yoshida,Haruko C. Kawato,(unknown),(unknown),(unknown),(unknown),Mayumi Kitagawa,Takahiko Seki,(unknown),Yoshinobu Shiose,Masashi Aonuma,Tsunehiko Soga	26
3	Discovery of novel dihydroimidazothiazole derivatives as p53–MDM2 protein–protein interaction inhibitors: Synthesis, biological evaluation and structure–activity relationships 2012 ·Bioorganic & Medicinal Chemistry Letters ·Masaki Miyazaki,Haruko C. Kawato,Hiroyuki Naito,Masahiro Ikeda,Masaya Miyazaki,Mayumi Kitagawa,Takahiko Seki,(unknown),Masashi Aonuma,Tsunehiko Soga	15
4	Lead optimization of novel p53-MDM2 interaction inhibitors possessing dihydroimidazothiazole scaffold 2012 ·Bioorganic & Medicinal Chemistry Letters ·Masaki Miyazaki,Hiroyuki Naito,(unknown),Haruko C. Kawato,(unknown),(unknown),Masaya Miyazaki,Mayumi Kitagawa,Takahiko Seki,(unknown),Masashi Aonuma,Tsunehiko Soga	25
5	E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines 2008 ·Oncogene ·Mayumi Kitagawa,Masashi Aonuma,(unknown),(unknown),Frank McCormick	75
6	Different antitumor activities of anti-bFGF neutralizing antibodies: heparin-binding domain provides an inefficient epitope for neutralization in vivo. 2000 ·PubMed ·Masashi Aonuma,Yoshino Yoshitake,K Nishikawa,(unknown)	6
7	Vascular endothelial growth factor overproduced by tumour cells acts predominantly as a potent angiogenic factor contributing to malignant progression 1999 ·International Journal of Experimental Pathology ·Masashi Aonuma	27
8	Tumorigenicity depends on angiogenic potential of tumor cells: dominant role of vascular endothelial growth factor and/or fibroblast growth factors produced by tumor cells 1998 ·Angiogenesis ·Masashi Aonuma,Michio Iwahana,Yutaka Nakayama,Kenji Hirotani,(unknown),Kenji Murakami,Masabumi Shibuya,Noriko Tanaka	10
9	Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. 1996 ·PubMed ·(unknown),Tomoko Takahashi,Sachiko Yamaguchi,Masashi Aonuma,Masabumi Shibuya	254
10	Pharmaceutical and biological properties of doxorubicin encapsulated in liposomes (L‐ADM): The effect of repeated administration on the systemic phagocytic activity and pharmacokinetics 1995 ·Biopharmaceutics & Drug Disposition ·(unknown),Hiroshi Kikuchi,Norio Suzuki,Ryo Atsumi,Masashi Aonuma,Yasuyoshi Kawato	7
11	A New Water‐soluble Camptothecin Derivative, DX‐8951f, Exhibits Potent Antitumor Activity against Human Tumors in vitro and in vivo 1995 ·PubMed ·Ikuo Mitsui,Eiji Kumazawa,Yasuhide Hirota,Masashi Aonuma,Masamichi Sugimori,Satoru Ohsuki,Kouichi Uoto,Akio Ejima,Hirofumi Terasawa,Keiki Sato	134
12	Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice 1991 ·Cancer Chemotherapy and Pharmacology ·Yasuyoshi Kawato,T Furuta,Masashi Aonuma,Megumi Yasuoka,Teruo Yokokura,Kensuke Matsumoto	137
13	Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.breakdown → 1991 ·PubMed ·Yasuyoshi Kawato,Masashi Aonuma,Yasuhide Hirota,Hiroshi Kuga,Keiki Sato	762
14	Production of SN-38, a Main Metabolite of the Camptothecin Derivative CPT-11, and Its Species and Tissue Specificities. 1991 ·Drug Metabolism and Pharmacokinetics ·Yasuyoshi Kawato,Masashi Aonuma,Kensuke Matsumoto,Keiki Sato	18

About Masashi Aonuma

Masashi Aonuma is a scholar working on Toxicology, Oncology and Molecular Biology, having authored 14 papers that have together received 1.5k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (5 papers), Cancer therapeutics and mechanisms (4 papers) and Click Chemistry and Applications (4 papers). The work is most often cited by research in Toxicology (125 citations), Oncology (875 citations) and Molecular Biology (1.2k citations). Masashi Aonuma has collaborated with scholars based in Japan, Germany and United States. Frequent co-authors include Yasuyoshi Kawato, Keiki Sato, Yasuhide Hirota, Hiroshi Kuga, Tomoko Takahashi, Masabumi Shibuya, Sachiko Yamaguchi, Kensuke Matsumoto, Teruo Yokokura and Mayumi Kitagawa. Their work appears in journals such as Oncogene, Bioorganic & Medicinal Chemistry and Bioorganic & Medicinal Chemistry Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact